Olaparib Pill

DRUG3 trials

Sponsors

Brown University, University of Pennsylvania, H. Lee Moffitt Cancer Center and Research Institute

Conditions

Adenocarcinoma of the ProstateHigh Grade Serous CarcinomaProstate CancerSmall Cell Lung Cancer Extensive StageSmall-cell Lung Cancer

Phase 1

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

Active, not recruitingNCT03923270

H. Lee Moffitt Cancer Center and Research InstituteSmall-cell Lung Cancer, Small Cell Lung Cancer Extensive Stage

Start: 2019-06-06End: 2026-12-01Updated: 2026-04-01

Phase 2

BrUOG 337: Olaparib Prior to Radical Prostatectomy For Advanced Prostate Cancer Defects in DNA Repair Genes

TerminatedNCT03432897

Brown UniversityAdenocarcinoma of the Prostate, Prostate Cancer

Start: 2018-05-25End: 2021-12-07Updated: 2025-07-08

Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer

CompletedNCT03462342

University of PennsylvaniaHigh Grade Serous Carcinoma

Start: 2018-03-09End: 2025-07-21Updated: 2026-03-17

Related Papers

Synchronous Oligometastasis and Oligoprogression as a Prognostic Marker in Patients With Extensive-Stage SCLC Treated With a Combination of Immune-Checkpoint Inhibitor and Chemotherapy (HOT2301)

JTO Clinical and Research Reports2024-09-072 citations

Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A).

Journal of Clinical Oncology2024-06-019 citations

Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation

Journal of Clinical Investigation2023-11-0736 citations

PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors

OncoImmunology2022-06-1846 citations

Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.

2021-10-0595 citations

Combination of PARP and ATR inhibitors (olaparib and ceralasertib) shows clinical activity in acquired PARP inhibitor-resistant recurrent ovarian cancer.

Journal of Clinical Oncology2021-05-2030 citations

Abstract A72: Combination ATR and PARP inhibitor (CAPRI) for recurrent, platinum-resistant ovarian cancer

Clinical Cancer Research2020-07-013 citations